(Q24247978)

4 August 2017

1 reference

title

Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus (English)

1 reference

4 August 2017

0 references

1 reference

1 reference

Edwin Ernest Salpeter

series ordinal

4

object named as

E Salpeter

1 reference

4 August 2017

1

S Salpeter

1 reference

4 August 2017

E Greyber

2

1 reference

4 August 2017

G Pasternak

series ordinal

3

1 reference

4 August 2017

language of work or name

English

0 references

publication date

21 July 2003

0 references

1 January 2002

1 reference

Cochrane Database of Systematic Reviews

4 August 2017

2003

0 references

published in

1 reference

4 August 2017

issue

2

1 reference

4 August 2017

page(s)

CD002967

1 reference

The efficacy of acarbose in the treatment of patients with non-insulin-dependent diabetes mellitus. A multicenter controlled clinical trial.

4 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967

Plasma t-PA and PAI-1 Antigen Concentrations in Non-Insulin Dependent Diabetic Patients: Effects of Treatment Modality on Fibrinolysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967

Acarbose for the treatment of type II diabetes: the results of a Canadian multi-centre trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967

Metformin decreases food consumption and induces weight loss in subjects with obesity with type II non-insulin-dependent diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967

Metformin increases insulin sensitivity and basal glucose clearance in Type 2 (non-insulin dependent) diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967

Efficacy of combined treatments in NIDDM patients with secondary failure to sulphonylureas. Is it predictable?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967

Comparison of bedtime insulin regimens in patients with type 2 diabetes mellitus. A randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967

Energy expenditure in non-insulin dependent diabetic subjects on metformin or sulphonylurea therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967

Pharmacologic therapy for type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967

Lactate homeostasis and lactic acidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967

Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967

7 January 2021

Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967

7 January 2021

Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967

7 January 2021

Meta-analysis of Observational Studies in Epidemiology: A Proposal for Reporting

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967

7 January 2021

Oral antidiabetic treatment in patients with coronary disease: time-related increased mortality on combined glyburide/metformin therapy over a 7.7-year follow-up

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967

7 January 2021

Worldwide experience of metformin as an effective glucose-lowering agent: a meta-analysis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967

7 January 2021

Daytime glibenclamide and bedtime NPH insulin compared to intensive insulin treatment in secondary sulphonylurea failure: a 1-year follow-up

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967

7 January 2021

Effect of metformin on intact proinsulin and des 31,32 proinsulin concentrations in subjects with non-insulin-dependent (type 2) diabetes mellitus.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967

7 January 2021

Monitoring of metabolic control in patients with non-insulin-dependent diabetes mellitus on oral hypoglycaemic agents: value of evening blood glucose determination.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967

7 January 2021

Effect of metformin on bile salt circulation and intestinal motility in type 2 diabetes mellitus.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967

7 January 2021

Adding metformin versus insulin dose increase in insulin-treated but poorly controlled Type 2 diabetes mellitus: an open-label randomized trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967

7 January 2021

Reversal of increased lymphocyte PC-1 activity in patients with type 2 diabetes treated with metformin.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967

7 January 2021

A comparison of statistical methods for combining event rates from clinical trials

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967

7 January 2021

A prospective study of the effect of 12 months treatment on serum lipids and apolipoproteins A-I and B in Type 2 (non-insulin-dependent) diabetes

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967

7 January 2021

Metformin reduces post-prandial insulin needs in type I (insulin-dependent) diabetic patients: Assessment by the artificial pancreas

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967

7 January 2021

Different effects of insulin and oral antidiabetic agents on glucose and energy metabolism in type 2 (non-insulin-dependent) diabetes mellitus

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967

7 January 2021

Prospective comparative study in NIDDM patients of metformin and glibenclamide with special reference to lipid profiles

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967

7 January 2021

Metformin for obese, insulin-treated diabetic patients: improvement in glycaemic control and reduction of metabolic risk factors.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967

7 January 2021

Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967

7 January 2021

Influence of phenformin and metformin on exercise induced lactataemia in patients with diabetes mellitus.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967

7 January 2021

Ciclazindol: An oral agent with weight reducing properties and hypoglycaemic activity

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967

7 January 2021

A comparison of treatment with metformin and gliclazide in patients with non-insulin-dependent diabetes.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967

7 January 2021

Comparative effects of phenformin, metformin and glibenclamide on metabolic rhythms in maturity-onset diabetics

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967

7 January 2021

Lactic acidosis in biguanide-treated diabetics: a review of 330 cases

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967

7 January 2021

The influence of dimethylbiguanide on phenprocoumon elimination and its mode of action. A drug interaction study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967

7 January 2021

Metformin-associated lactic acidosis in Sweden 1977-1991

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967

7 January 2021

Low dose metformin in the treatment of type II non-insulin-dependent diabetes: clinical and metabolic evaluations

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967

7 January 2021

COMBINED TRIAL OF ACETOHEXAMIDE AND TWO DIGUANIDE PREPARATIONS

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967

7 January 2021

Causes of weight gain during insulin therapy with and without metformin in patients with Type II diabetes mellitus

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967

7 January 2021

A comparison of preconstituted, fixed combinations of low-dose glyburide plus metformin versus high-dose glyburide alone in the treatment of type 2 diabetic patients.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967

7 January 2021

Intensive insulin therapy combined with metformin in obese type 2 diabetic patients.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967

7 January 2021

Effectiveness of glibenclamide on myocardial ischemic ventricular arrhythmias in non-insulin-dependent diabetes mellitus

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967

7 January 2021

Metformin-induced changes in serum lipids, lipoproteins, and apoproteins in non-insulin-dependent diabetes mellitus

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967

7 January 2021

Metformin improved insulin resistance in type I, insulin-dependent, diabetic patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967

7 January 2021

The impact of metformin therapy on hepatic glucose production and skeletal muscle glycogen synthase activity in overweight type II diabetic patients.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967

7 January 2021

Study of the effect of metformin on platelet aggregation in insulin-dependent diabetics

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967

7 January 2021

Lessons from UK prospective diabetes study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967

7 January 2021

Different effect of acute and chronic oral metformin administration on glucose and insulin response to bread and to pasta in non-insulin dependent diabetic patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967

7 January 2021

The effect of metformin on liver blood flow in vivo in normal subjects and patients with non insulin dependent diabetes

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967

7 January 2021

Relationship between plasminogen activator inhibitor type-1 plasma levels and the lipoprotein(a) concentrations in non-insulin-dependent diabetes mellitus

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967

7 January 2021

Assessing the quality of reports of randomized clinical trials: is blinding necessary?

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967

7 January 2021

Re-evaluation of a biguanide, metformin: mechanism of action and tolerability

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967

7 January 2021

Efficacy of 24-week monotherapy with acarbose, metformin, or placebo in dietary-treated NIDDM patients: the Essen-II Study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967

7 January 2021

Efficacy of metformin in type II diabetes: results of a double-blind, placebo-controlled, dose-response trial.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967

7 January 2021

Effects of metformin on the pathways of glucose utilization after oral glucose in non-insulin-dependent diabetes mellitus patients.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967

7 January 2021

Effects of gliclazide versus metformin on the clinical profile and lipid peroxidation markers in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967

7 January 2021

FIBRINOLYTIC EFFECT OF METFORMIN IN CORONARY-ARTERY DISEASE

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967

7 January 2021

Comparison of chlorpropamide and metformin treatment on weight and blood-glucose response of uncontrolled obese diabetics

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967

7 January 2021

Sucrose taken during mixed meal has no additional hyperglycaemic action over isocaloric amounts of starch in well-controlled diabetics

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967

7 January 2021

Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967

7 January 2021

Combined metformin and insulin therapy for patients with type 2 diabetes mellitus.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967

7 January 2021

A retrospective chart review of uncontrolled use of metformin as an add-on therapy in type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967

7 January 2021

Metformin as secondary therapy in a defined population with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967

7 January 2021

Meformin, plasma glucose and free fatty acids in type II diabetic out-patients: results of a clinical study.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967

7 January 2021

Effect of metformin on glycaemic control in type 2 diabetes in daily practice: a retrospective study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967

7 January 2021

Metformin: effects on cardiovascular risk factors in patients with non-insulin-dependent diabetes mellitus

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967

7 January 2021

Addition of Benfluorex to Biguanide Improves Glycemic Control in Obese Non–Insulin-Dependent Diabetes

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967

7 January 2021

Small weight loss on long-term acarbose therapy with no change in dietary pattern or nutrient intake of individuals with non-insulin-dependent diabetes

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967

7 January 2021

Folate administration reduces circulating homocysteine levels in NIDDM patients on long-term metformin treatment

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967

7 January 2021

Contra-indications to metformin therapy are largely disregarded

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967

7 January 2021

Comparison of acarbose and metformin in patients with Type 2 diabetes mellitus insufficiently controlled with diet and sulphonylureas: a randomized, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967

7 January 2021

A comparison of metformin versus guar in combination with sulphonylureas in the treatment of non insulin dependent diabetes.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967

7 January 2021

Glucagon-like peptide 1 and its potential in the treatment of non-insulin-dependent diabetes mellitus.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967

7 January 2021

Therapeutic effect of glibenclamide in a fixed combination with metformin or phenformin in NIDDM patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967

7 January 2021

Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967

7 January 2021

Metabolic effects of metformin in non-insulin-dependent diabetes mellitus

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967

7 January 2021

https://api.crossref.org/works/10.1002%2F14651858.CD002967

1 reference

7 January 2021

Lactic acidosis in patients with diabetes treated with metformin

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967

7 January 2021

Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967

7 January 2021

Determination of Plasma Metformin by a New Cation-Exchange HPLC Technique

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967

7 January 2021

Sulphonylurea failure in type 2 diabetes: treatment with a basal insulin supplement.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967

7 January 2021

The effect of glibenclamide and metformin on serum lipoproteins in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967

7 January 2021

The effects of metformin on adipocyte insulin action and metabolic control in obese subjects with type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967

7 January 2021

Placebo-controlled trial of the effects of guar gum and metformin on fasting blood glucose and serum lipids in obese, type 2 diabetic patients.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967

7 January 2021

Comparison of tolbutamide and metformin in elderly diabetic patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967

7 January 2021

Metformin Causes a Reduction in Basal and Post-venous Occlusion Plasminogen Activator Inhibitor-1 in Type 2 Diabetic Patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967

7 January 2021

The effect of intravenous metformin on glucose metabolism during hyperglycaemia in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967

7 January 2021

The Effects of Dexfenfluramine on Blood Glucose Control in Patients with Type 2 Diabetes

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967

7 January 2021

Antihyperglycaemic efficacy, response prediction and dose-response relations of treatment with metformin and sulphonylurea, alone and in primary combination.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967

7 January 2021

Obese patients with type 2 diabetes poorly controlled by insulin and metformin: effects of adjunctive dexfenfluramine therapy on glycaemic control

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967

7 January 2021

One-year acarbose treatment raises fasting serum acetate in diabetic patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967

7 January 2021

Metformin in treatment of diabetes mellitus

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967

7 January 2021

Comparison of metformin and chlorpropamide in non-obese, maturity-onset diabetics uncontrolled by diet

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967

7 January 2021

Epidemiology of adverse drug reactions to phenformin and metformin

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967

7 January 2021

Effect of metformin on insulin receptor binding and glycaemic control in type II diabetes

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967

7 January 2021

Circadian Variation of Glucose, Insulin, and Free Fatty Acids During Long-term Use of Oral Hypoglycaemic Agents in Diabetes Mellitus

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967

7 January 2021

Effects of improved glycaemic control on calcium and magnesium homeostasis in type II diabetes

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967

7 January 2021

Metformin treatment in NIDDM patients with mild renal impairment

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967

7 January 2021

Antihyperglycemic treatment in diabetics with coronary disease: increased metformin-associated mortality over a 5-year follow-up.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967

7 January 2021

Pharmacokinetics and pharmacodynamics of metformin in healthy subjects and patients with noninsulin-dependent diabetes mellitus

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967

7 January 2021

The reduction of low density lipoprotein cholesterol by metformin is maintained with long-term therapy.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967

7 January 2021

Metformin efficacy and tolerance in obese non-insulin dependent diabetics: a comparison of two dosage schedules

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967

7 January 2021

Metformin normalizes insulin binding to monocytes from obese nondiabetic subjects and obese type II diabetic patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967

7 January 2021

Mechanism of metformin action in obese and lean noninsulin-dependent diabetic subjects.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967

7 January 2021

THE EFFECT OF METFORMIN ON WEIGHT LOSS IN OBESITY

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967

7 January 2021

Clinical pharmacokinetics of metformin

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967

7 January 2021

Insulin Receptor Binding to Monocytes, Insulin Secretion, and Glucose Tolerance Following Metformin Treatment: Results of a Double-Blind Cross-Over Study in Type II Diabetics

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967

7 January 2021

Mechanism of metformin action in non-insulin-dependent diabetes

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967

7 January 2021

Acute antihyperglycemic mechanisms of metformin in NIDDM. Evidence for suppression of lipid oxidation and hepatic glucose production

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967

7 January 2021

Metformin reduces systemic methylglyoxal levels in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967

7 January 2021

A comparison of troglitazone and metformin on insulin requirements in euglycemic intensively insulin-treated type 2 diabetic patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967

7 January 2021

Effect of metformin on insulin-stimulated glucose turnover and insulin binding to receptors in type II diabetes

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967

7 January 2021

Effect of metformin on carbohydrate and lipoprotein metabolism in NIDDM patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967

7 January 2021

Metabolic control in diabetic subjects in three Swedish areas with high, medium, and low sales of antidiabetic drugs

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967

7 January 2021

Double-blind evaluation of efficacy and tolerability of metformin in NIDDM.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967

7 January 2021

Comparison of combined therapies in treatment of secondary failure to glyburide

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967

7 January 2021

Effects of metformin on insulin resistance, risk factors for cardiovascular disease, and plasminogen activator inhibitor in NIDDM subjects. A study of two ethnic groups.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967

7 January 2021

Metabolic and hemodynamic effects of metformin and glibenclamide in normotensive NIDDM patients.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967

7 January 2021

Effect of metformin on postprandial lipemia in patients with fairly to poorly controlled NIDDM.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967

7 January 2021

Therapeutic comparison of metformin and sulfonylurea, alone and in various combinations. A double-blind controlled study.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967

7 January 2021

Comparison of insulin with or without continuation of oral hypoglycemic agents in the treatment of secondary failure in NIDDM patients.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967

7 January 2021

Role of metformin accumulation in metformin-associated lactic acidosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967

7 January 2021

Metformin's effects on glucose and lipid metabolism in patients with secondary failure to sulfonylureas.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967

7 January 2021

The effects of high- and medium-dose metformin therapy on cardiovascular risk factors in patients with type II diabetes.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967

7 January 2021

The effect of metformin on adipose tissue metabolism and peripheral blood flow in subjects with NIDDM.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967

7 January 2021

A comparison of acarbose versus metformin as an adjuvant therapy in sulfonylurea-treated NIDDM patients.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967

7 January 2021

Metformin improves hemodynamic and rheological responses to L-arginine in NIDDM patients.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967

7 January 2021

Results of a placebo-controlled study of the metabolic effects of the addition of metformin to sulfonylurea-treated patients. Evidence for a central role of adipose tissue

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967

7 January 2021

Comparative effects of glibenclamide and metformin on ambulatory blood pressure and cardiovascular reactivity in NIDDM

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967

7 January 2021

Contraindications to metformin therapy in patients with NIDDM

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967

7 January 2021

Metformin and lactic acidosis: guilt by association?

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967

7 January 2021

No relationship between carbohydrate intake and effect of acarbose on HbA1c or gastrointestinal symptoms in type 2 diabetic subjects consuming 30-60% of energy from carbohydrate.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967

7 January 2021

Lactic acidosis rates in type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967

7 January 2021

Efficacy and safety of acarbose in metformin-treated patients with type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967

7 January 2021

Effect of troglitazone on microalbuminuria in patients with incipient diabetic nephropathy.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967

7 January 2021

UKPDS 28: a randomized trial of efficacy of early addition of metformin in sulfonylurea-treated type 2 diabetes. U.K. Prospective Diabetes Study Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967

7 January 2021

The effects of metformin on glycemic control and serum lipids in insulin-treated NIDDM patients with suboptimal metabolic control.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967

7 January 2021

Acarbose in NIDDM patients with poor control on conventional oral agents. A 24-week placebo-controlled study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967

7 January 2021

Further evidence for a central role of adipose tissue in the antihyperglycemic effect of metformin

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967

7 January 2021

Irreversibility of the defect in glycogen synthase activity in skeletal muscle from obese patients with NIDDM treated with diet and metformin

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967

7 January 2021

Effect of repaglinide addition to metformin monotherapy on glycemic control in patients with type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967

7 January 2021

Efficacy of metformin in the treatment of NIDDM. Meta-analysis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967

7 January 2021

First 20 months' experience with use of metformin for type 2 diabetes in a large health maintenance organization

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967

7 January 2021

Metformin added to insulin therapy in poorly controlled type 2 diabetes

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967

7 January 2021

Metformin and lipoprotein(a) levels

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967

7 January 2021

Incidence of lactic acidosis in metformin users

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967

7 January 2021

A randomized double-blind trial of acarbose in type 2 diabetes shows improved glycemic control over 3 years (U.K. Prospective Diabetes Study 44)

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967

7 January 2021

Nateglinide alone and in combination with metformin improves glycemic control by reducing mealtime glucose levels in type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967

7 January 2021

The synergistic effect of miglitol plus metformin combination therapy in the treatment of type 2 diabetes

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967

7 January 2021

Outcome of metformin-facilitated reinitiation of oral diabetic therapy in insulin-treated patients with non-insulin-dependent diabetes mellitus

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967

7 January 2021

United Kingdom Prospective Diabetes Study 24: a 6-year, randomized, controlled trial comparing sulfonylurea, insulin, and metformin therapy in patients with newly diagnosed type 2 diabetes that could not be controlled with diet therapy. United Kingd

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967

7 January 2021

Effects of metformin in patients with poorly controlled, insulin-treated type 2 diabetes mellitus. A randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967

7 January 2021

10.1002/14651858.CD002967

Identifiers

DOI

1 reference

4 August 2017

1 reference